



For Immediate Release

Tergus COO Honored by Alma Mater

Dr. Kailas Thakker given UAA-ICT Distinguished Alumnus Award for entrepreneurship

Durham, North Carolina – May 19, 2016 Kailas Thakker, PhD, was been awarded a Distinguished Alumnus Award. The alumni association of the Institute of Chemical Technology (ICT) is honoring Dr. Thakker's long tenure as an entrepreneur starting with her founding Analytical Solutions in 1994 followed by serving as a s COO and co-founder of Tergus Pharma (www.terguspharma.com). Tergus is the industry leader in topical development, formulation, analysis, testing and clinical supply manufacturing. Tergus Pharma was born as a strategic move to elevate Analytical Solutions and to provide one- stop- shop for Topical product development to pharmaceutical industry.

Dr. Thakker is a pioneer in functional testing for semi-solids, which led her to co-founding Tergus. Under her leadership, Tergus has emerged as the recognized global leader in developing release rate methods for semi-solid dosage forms. She earned her undergraduate degree at ICT.

She was involved in the development of in Vitro Release Testing (IVRT), recognized as an essential testing protocol for Semi-solid dosage forms. Her work led to the development of the SUPAC-SS guidance document that the pharmaceutical industry follows. She is a member of the USP's Advisory Panel and helped draft chapters 3 and 1724. She was a member of USP's Expert Committee on Dosage forms for the 2010-2015 revision cycle.

Dr. Thakker earned her PhD in Pharmaceutical Chemistry at the University of Kansas with Dr. Takeru Higuchi, known as the father of modern pharmaceuticals. She worked at US Pharmacopeia for 12 years, where she specialized in the development and validation of dissolution methods in the Drug Research and Testing Laboratory. Dr. Thakker has also held leadership positions at Sphinx Pharmaceuticals and BioAnalytika Laboratories.

"I am honored to receive the Distinguished Alumnus award for entrepreneurship," said Kailas Thakker, PhD, COO and co-founder of Tergus. "The other honorees are leaders in their field and I am very pleased to be in their company."

Under the leadership of Dr. Thakker and Dr. Vijendra Nalamonthu, CEO, Tergus has enjoyed strong growth for the past few years in all phases of product development focusing on semisolid dosage forms. It continues to grow its footprint, recently expanding to a more than 26,000 square-foot facility that includes the largest capability in the industry for IVRT and skin permeation studies, state of the art R&D laboratories and a class 100,000 certified manufacturing suite. Through use of IVRT and other physico-chemical techniques, Tergus has championed the concept of Quality by Design for topical pharmaceuticals and continues to innovate and develop strategies that result in greater success for its clients.

Tergus offers complete topical pharmaceutical consulting services, development, formulation, analytical R&D, In Vitro Release Testing (IVRT), skin biology and cGMP clinical supplies manufacturing. The company has capability to produce clinical supplies up to 150kg using their state of the art manufacturing equipment. The company's motto is "Think Topical, Think Tergus."

About Tergus

Tergus (www.terguspharma.com) is the market leader in full-service topical pharmaceutical research, development, testing, analysis and manufacturing. The company has more than 20 years in business located in a state-of-the-art laboratory facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality and results for clients from formulation through manufacturing. Tergus pioneered Quality by Design (QbD) protocols for semi-solid delivery forms and has the largest bank of In Vitro Release Testing (IVRT) Franz Diffusion cells. The company's motto is "Think Topical. Think Tergus."

###